Economic impact of hyperhomocysteinemia in Switzerland

Cardiovascular Drugs and Therapy

Volumn 19, Issue 5, 2005, Pages 365-369

  Szucs, Thomas D ^a   Käser, Andreas ^b   Riesen, Walter F ^c  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Palas Clinic Group   (Switzerland)

^c Kantonal Hospital   (Switzerland)

Author keywords

Atherosclerosis; Cardiovascular risk; Cost effectiveness; Costs; Homocysteine; Hyperhomocysteinemia; Myocardial infarction; Prevention; Stroke; Swiss healthcare system

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST OF ILLNESS; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HEART INFARCTION; HUMAN; HYPERHOMOCYSTEINEMIA; INCIDENCE; MALE; PRIORITY JOURNAL; STROKE; SWITZERLAND;

ADOLESCENT; ADULT; CEREBROVASCULAR ACCIDENT; COST OF ILLNESS; FEMALE; HUMANS; HYPERHOMOCYSTEINEMIA; INCIDENCE; MALE; MIDDLE AGED; MODELS, ECONOMIC; MYOCARDIAL INFARCTION; RISK FACTORS; SWITZERLAND;

EID: 29744433830     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-3682-y     Document Type: Article

References (13)

1. Sagmeister M, Gessner U, Oggier W, Horisberger B, Gutzwiller F. An economic analysis of ischaemic heart disease in Switzerland. Eur Heart J 1997;18(7):1102-1119.
2. Murray CJ, Lopez AD. Regional patterns of disability-free life expectancy and disability-adjusted life expectancy: Global Burden of Disease Study. Lancet 1997;349(9062):1347-1352.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). Jama 1986;256(20):2823-2828.
4. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Jama 1995;274(13):1049-1057.
5. McCully KS. Homocysteine and vascular disease. NatMed 1996;2(4):386-389.
6. Murray CJ, Lopez AD. Global Health Statistics. Harvard University Press, 1996.
7. Swiss Office of Statistics (BFS), Statitistisches Jahrbuch der Schweiz. Neue Zürcher Zeitung, 1999.
8. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. Jama 1992;268(7):877-881.
9. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Ecksfeldt JH et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98(3):204-210.
10. Szucs TD, Gutzwiller F. Grundlagen der Kosten-Nutzen-Analyse bei der Langzeitbehandlung von Risikofaktoren. Schweiz Med Wochenschr 1998;128(49):1958-1964.
11. Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36:758-765.
12. Bostom AG, Liaugaudas G, Jacques PF, Rosenberg IH, Selhub J. Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid fortified cereal grain flour [abstract]. Circulation 2001;103:1367.
13. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L, Goldman L. Cost-effectiveness of vitamin therapy to lower plasma homocusteine levels for the prevention of coronary heart disease: Effect of grain fortification and beyond. JAMA 2001;286:936-943.